Category: Press Releases

Turin, 19^th October 2022. Iveco Group N.V. (MI: IVG) announces that its financial results for the Third Quarter of 2022 will be presented on Wednesday, 9th November 2022.

The press release, presentation and other earnings’ supporting documents are expected to be posted on the corporate website at Financials | Iveco Group in the morning. A live audio webcast of the 2022 Third Quarter results conference call will take place later the same day at 6:00pm CET / 5:00pm GMT.

Details for accessing the webcast presentation are available at the following address:
Q3 2022 IVECO GROUP webcast

For those unable to take part in the live session, a replay will be available in the Investors section of the company website (www.ivecogroup.com) following the conference call.

Iveco Group N.V. (MI: IVG) is the home of unique people and brands that power your business and mission to advance a more sustainable society. The eight brands are each a major force in its specific business: IVECO, a pioneering commercial vehicles brand that designs, manufactures, and markets heavy, medium, and light-duty trucks; FPT Industrial, a global leader in a vast array of advanced powertrain technologies in the agriculture, construction, marine, power generation, and commercial vehicles sectors; IVECO BUS and HEULIEZ, mass-transit and premium bus and coach brands; IDV, for highly-specialised defence and civil protection equipment; ASTRA, a leader in large-scale heavy-duty quarry and construction vehicles; MAGIRUS, the industry-reputed firefighting vehicle and equipment manufacturer; and IVECO CAPITAL, the financing arm which supports them all. Iveco Group employs approximately 34,000 people around the world and has 28 manufacturing plants and 29 R&D centres. Further information is available on the Company’s website www.ivecogroup.com

Media Contacts:
Francesco Polsinelli, Tel: +39 335 1776091
Fabio Lepore, Tel: +39 335 7469007
E-mail: mediarelations@ivecogroup.com

Investor Relations:
Federico Donati, Tel: +39 011 0073539
E-mail: investor.relations@ivecogroup.com

Attachment

• 20221019_PR_Iveco_Group_2022_Q3_Announcement

The enhanced Cellebrite investigative evidence management solution further accelerates time to evidence, reduces backlogs, and empowers agencies to utilize resources more efficiently

PETAH TIKVA, Israel and TYSONS CORNER, Va., Oct. 19, 2022 (GLOBE NEWSWIRE) — Cellebrite DI Ltd. (Nasdaq: CLBT), a global leader in Digital Intelligence (DI) solutions for the public and private sectors, today announced the release of the next generation of Cellebrite Guardian, which provides quicker time to evidence (TTE) as it loads evidence within just seconds of receipt and further simplifies workflows to accelerate time to justice.

The latest enhancements create increased flexibility for law enforcement and help them secure privacy as they are able to harness the power of the solution to simplify and streamline end-to-end processes and key pain points in the investigative workflow, including physical duplication, transportation of evidence, and time-consuming evidence review.

We expect Cellebrite Guardian will accelerate TTE by more than 5 times compared to traditional methods¹, enabling agencies to go from collection to collaboration in 2 hours (total time spent on case) compared to the current average TTE of 11 hours. Cellebrite Guardian also allows agencies to use their resources more efficiently.

Without the restraints of limited duration of storage and access to extractions, Cellebrite Guardian puts the customer at the center, allowing them to better address numerous evidence management challenges no matter how big the case or how long it takes.

Upper Allen Township Police Department Lieutenant Brian Barnes stated, “One person solving the case just isn’t the reality anymore. Modern investigations require team members from multiple disciplines, effectively collaborating, to bring justice to a victim. Often these cases involve digital evidence. Cellebrite Guardian is not only managing the critical relationship between investigator and examiner, but also ensuring that digital intelligence is immediately actionable regardless of hardware or skillset. Investigators reviewing phone extractions in a web browser, and quickly providing access to prosecutors via the cloud for instant review, forever changes the inefficient paradigm of yesterday.”

“The faster review capabilities for Cellebrite Guardian are critical for accelerating the time to justice in any investigation,” said Todd Bailey, Vice President and Head of Investigation and Evidence Management Solutions at Cellebrite. “Previously, Guardian had transformed hours of manual review processes into minutes. With our latest release, we have sped up those minutes into mere seconds. This speed, in combination with Guardian’s inbuilt flexibility, enables any agency to resolve cases faster.”

To learn more about Cellebrite Guardian, visit here.

About Cellebrite

Cellebrite’s (NASDAQ: CLBT) mission is to enable its customers to protect and save lives, accelerate justice, and preserve privacy in communities around the world. We are a global leader in Digital Intelligence solutions for the public and private sectors, empowering organizations in mastering the complexities of legally sanctioned digital investigations by streamlining intelligence processes. Trusted by thousands of leading agencies and companies worldwide, Cellebrite’s Digital Intelligence platform and solutions transform how customers collect, review, analyze and manage data in legally sanctioned investigations. To learn more visit us at www.cellebrite.com, https://investors.cellebrite.com, or follow us on Twitter at @Cellebrite.

Caution Regarding Forward Looking Statements
This document includes “forward looking statements” within the meaning of the “safe harbor” provisions of the United States Private Securities Litigation Reform Act of 1995. Forward looking statements may be identified by the use of words such as “forecast,” “intend,” “seek,” “target,” “anticipate,” “will,” “appear,” “approximate,” “foresee,” “might,” “possible,” “potential,” “believe,” “could,” “predict,” “should,” “could,” “continue,” “expect,” “estimate,” “may,” “plan,” “outlook,” “future” and “project” and other similar expressions that predict, project or indicate future events or trends or that are not statements of historical matters. Such forward looking statements include estimated financial information. Such forward looking statements with respect to revenues, earnings, performance, strategies, prospects, and other aspects of Cellebrite’s business are based on current expectations that are subject to risks and uncertainties. A number of factors could cause actual results or outcomes to differ materially from those indicated by such forward looking statements. These factors include, but are not limited to: Cellebrite’s ability to keep pace with technological advances and evolving industry standards; Cellebrite’s material dependence on the acceptance of its solutions by law enforcement and government agencies; real or perceived errors, failures, defects or bugs in Cellebrite’s DI solutions; Cellebrite’s failure to maintain the productivity of sales and marketing personnel, including relating to hiring, integrating and retaining personnel; uncertainties regarding the impact of macroeconomic and/or global conditions, including COVID-19 and military actions involving Russia and Ukraine; intense competition in all of Cellebrite’s markets; the inadvertent or deliberate misuse of Cellebrite’s solutions; political and reputational factors related to Cellebrite’s business or operations; risks relating to estimates of market opportunity and forecasts of market growth; Cellebrite’s ability to properly manage its growth; risks associated with Cellebrite’s credit facilities and liquidity; Cellebrite’s reliance on third-party suppliers for certain components, products, or services; challenges associated with large transactions and long sales cycle; risks that Cellebrite’s customers may fail to honor contractual or payment obligations; risks associated with a significant amount of Cellebrite’s business coming from government customers around the world; risks related to Cellebrite’s intellectual property; security vulnerabilities or defects, including cyber-attacks, information technology system breaches, failures or disruptions; the mishandling or perceived mishandling of sensitive or confidential information; the complex and changing regulatory environments relating to Cellebrite’s operations and solutions; the regulatory constraints to which we are subject; risks associated with different corporate governance requirements applicable to Israeli companies and risks associated with being a foreign private issuer and an emerging growth company; market volatility in the price of Cellebrite’s shares; changing tax laws and regulations; risks associated with joint, ventures, partnerships and strategic initiatives; risks associated with Cellebrite’s significant international operations; risks associated with Cellebrite’s failure to comply with anti-corruption, trade compliance, anti-money-laundering and economic sanctions laws and regulations; risks relating to the adequacy of Cellebrite’s existing systems, processes, policies, procedures, internal controls and personnel for Cellebrite’s current and future operations and reporting needs; and other factors, risks and uncertainties set forth in the section titled “Risk Factors” in Cellebrite’s annual report on form 20-F filed with the SEC on March 29, 2022 and in other documents filed by Cellebrite with the U.S. Securities and Exchange Commission (“SEC”), which are available free of charge at www.sec.gov. You are cautioned not to place undue reliance upon any forward looking statements, which speak only as of the date made, in this communication or elsewhere. Cellebrite undertakes no obligation to update its forward looking statements, whether as a result of new information, future developments or otherwise, should circumstances change, except as otherwise required by securities and other applicable laws.

Cellebrite Media 
Victor Cooper
Public Relations and Corporate Communications Director
Victor.Cooper@cellebrite.com
+1 404.804.5910

Investors
Investor Relations
investors@cellebrite.com

¹ Research findings 2022, Cellebrite in co-operation with anonymous mid-sized US agency

Leading experts will shed light on topics in the QA space that are close to their hearts

San Francisco, Oct. 19, 2022 (GLOBE NEWSWIRE) — LambdaTest, the leading continuous quality testing cloud platform, announced the launch of Voices of Community, a monthly talk with testing and QA experts from across the globe.

The once-in-a-month free live webinar is hosted by Manoj Kumar, VP – Developer Relations, LambdaTest. Through Voices of Community, the organization hopes to bring experts together to talk about the lessons from the past, discuss the present scenario, and talk about where the industry is headed.

“The community is at the center of everything we do at LambdaTest. Voices of Community will bring community experts to talk on topics that they hold close to their hearts. These are people who have built the platforms and tools we use day in and day out at our jobs. We can’t wait for the community to soak in all the learning,” said Manoj Kumar. Manoj is also a member of the project leadership committee for Selenium and an Appium committer.

In the first episode of Voices of Community, John Ferguson Smart, the author of the best-seller, BDD in Action, as well as Jenkins: The Definitive Guide and Java Power Tools and the creator of the Serenity BDD test automation framework joined Manoj. In the upcoming episode, the renowned testing icon and creator of Selenium WebDriver, Simon Stewart, will be joining in as the guest speaker.

“One thing that I learnt while working on Selenium is that community is the biggest factor for a project’s success. More importantly, I learnt that community is also one of the biggest factors for personal success. Being able to listen and learn from other people’s experience, applying lessons from their insights, learning about what works and what doesn’t, and finding out about the trends in our industry helps us grow as developers and testers. That’s why I’m excited to be part of “Voices of Community” by LambdaTest. I hope that you enjoy and learn from what this initiative will offer the testing community. Wishing them — and you! — every success and the best of luck! Onwards and upwards!,” said Simon Stewart, Creator, Selenium WebDriver.

“The testing and developer landscape is always in a state of flux. Being a QA in today’s digital-led world means that one has to reinvent themselves constantly. The community plays a vital role as people from different walks of life can influence and nudge you to stay constantly updated. Voices of Community by LambdaTest is a great initiative that will bring experts from within the community to share the lessons from the past, discuss the present scenario, and talk about where the industry is headed,” said John Ferguson Smart, Creator, BDD Serenity.

To explore more about the Voices of Community, visit here and to register for the upcoming session with Simon Stewart, visit here.

About LambdaTest

LambdaTest is the leading continuous quality testing cloud platform that helps developers and testers ship code faster. Over 10,000+ customers, one million users across 130+ countries rely on LambdaTest for their testing needs.

LambdaTest platform provides secure, scalable, and insightful test orchestration for
customers at different points in their DevOps (CI/CD) lifecycle:-

● Browser & App Testing Cloud allows users to run both manual and
automated tests of web and mobile apps across 3000+ different browsers,
real devices, and operating system environments.

● HyperExecute helps customers run and orchestrate test grids in the cloud
for any platform and programming language at blazing-fast speeds to cut
down on quality test time, helping developers build software faster. 

For further information please contact the LambdaTest press office: Bilal Mahmood on press@lambdatest.com or +44 (0) 20 3640 7759 and +44 (0) 771 400 7257.

Call for a WHO Resolution to kick-start necessary action

CAPE TOWN, South Africa, Oct. 19, 2022 (GLOBE NEWSWIRE) — The Global Self-Care Federation (GSCF) has today launched the second edition of the Self-Care Readiness Index, examining how self-care policies are being implemented across the world. The first and second editions of the Index, together covering 20 countries, demonstrate very clearly that there is a widespread lack of a coherent view of self-care and its benefits.

Malebona Precious Matsoso,  Former Director General of the Department of Health, South Africa said: “Taking collective action to integrate self-care into the global healthcare continuum is the logical and critical next step as we move to re-evaluate the status of our healthcare systems. To support this, there needs to be a global compact on self-care at the international level, this will provide a frame for national-level policymakers to operate within.”

The Self-Care Readiness Index (SCRI) is a research and policymaking tool which explores the key enablers of self-care in support of designing a better model for healthcare systems. It evaluates countries based on four self-care enablers, supported by measurable indicators of self-care readiness. The four enablers are stakeholder support and adoption; consumer and patient empowerment; comprehensive self-care health policies; and the appropriate regulatory environment.

Manoj Raghunandanan, Chair Elect at the Global Self-Care Federation said, “Self-care is a simple concept but it is not easy. It takes a concerted effort by governments, healthcare professionals, academia, industry, and ultimately, the population at large. But the potential rewards are high: better patient outcomes, more efficient healthcare systems and improved access to care.”

Raghunandanan continued, “This research is clear: self-care is highly effective and efficient. In developed countries, empowering people to care for their own health reduces pressure on healthcare systems. And it is critical for low- and middle-income countries, where self-care can be an incredibly important tool for delivering the goal of universal health coverage, and may actually be the only healthcare option available.”

The second edition of the SCRI covered Australia, Canada, Colombia, Germany, India, Indonesia, Kenya, Mexico, Singapore and the United Arab Emirates. This complemented the countries covered in the first edition: Brazil, China, Egypt, France, Nigeria, Poland, South Africa, Thailand, the United Kingdom and the United States.

Judy Stenmark, Director General at GSCF continued, “Self-care has to be a political priority for every single government across the world. And we are calling on WHO to urgently adopt a Resolution to support the synchronisation of self-care policies to create the momentum for this much-needed change.”

The new SCRI is available here. It is a wide-ranging and comprehensive report, covering in detail the four enablers and the extent of self-care penetration in each of the 10 countries. It is the result of thorough research into each country’s healthcare system, led by GSCF and in collaboration with the World Health Organization’s Traditional, Complementary, and Integrative Medicines and Integrated Health Services Unit, with the support of the eminent healthcare professionals who made up the Expert Advisory Committee.

Contact Information:
Catherine Laverty
claverty@selfcarefederation.org

This content was issued through the press release distribution service at Newswire.com.

Nucleome Therapeutics raises oversubscribed £37.5 million Series A financing to decode the dark matter of the human genome and deliver first–in–class precision medicines

• Financing led by M Ventures alongside other new investors JJDC, Pfizer Ventures and British Patient Capital, and including founding investor Oxford Science Enterprises
• Nucleome’s pioneering platform seeks to identify direct genetic linkages to disease-associated genes for drug discovery
• Funds will advance Nucleome’s autoimmune disease programmes and fuel expansion of its dark genome atlas

Oxford, UK, 19 October 2022 – Nucleome Therapeutics Limited, (‘Nucleome’ or ‘the Company’), a biotechnology company decoding the dark matter of the human genome to discover first-in-class precision medicines, today announces it has closed an oversubscribed £37.5 million Series A financing round. The funds will be used to advance the Company’s autoimmune disease programmes, fuel expansion of its dark genome atlas and further develop its pioneering platform.

The financing was led by new investor M Ventures, the strategic, corporate venture capital arm of Merck KGaA, with participation from Johnson and Johnson Innovation-JJDC, Inc. (“JJDC”), the strategic venture capital arm of Johnson & Johnson; Pfizer Ventures, the venture group of Pfizer; British Patient Capital, through its Future Fund: Breakthrough programme; and founding investor Oxford Science Enterprises.

Nucleome has the unique ability to discover and validate first-in-class targets through genetics, by investigating the ‘dark’ region of the human genome, which does not encode for proteins but contains 90% of disease-associated genetic changes. Understanding the role of these genetic variants has been a long-standing challenge, hindering the translation of the human genome into useful drug discovery insights.

Nucleome’s breakthrough platform combines pioneering 3D genome technology and machine learning to shed light on these variants by directly linking genes to diseases and mapping pathways with unprecedented precision for drug discovery.

“We have already made significant progress by mapping genes to genetics in a number of human immune cell types and discovering the first wave of potential first-in-class autoimmune disease targets,” said Dr Danuta Jeziorska, Chief Executive Officer and Co-founder of Nucleome Therapeutics.  “The completion of this oversubscribed round with such a high-calibre group of global life science investors is a recognition of the significance of Nucleome’s platform and its potential to support the development of an exciting portfolio of first-in-class targets for autoimmune diseases.”

Dr Bauke Anninga, Principal at M Ventures, commented: “Nucleome’s differentiated platform technology has the potential to fundamentally shift the way we discover and develop precision medicines. Unlocking the value of the largely unexplored territory of the genome can lead to the identification of high-value drug targets. Nucleome’s platform adds 3D genomic information to a wealth of available genomic data, uncovering a new dimension of information that is disease as well as cell type-specific. We are excited to lead this financing, and alongside our co-investors, partner with Nucleome’s exceptional team to advance their target and drug discovery programmes to bring transformative treatments to patients.”

Dr Jonathan Hepple, Non-executive Director at Nucleome and Advisor to Oxford Science Enterprises, added: “Since its founding in 2019, Nucleome has advanced to become a leader in 3D genomics analysis. Publications in high-impact journals have validated its groundbreaking technology and ability to identify new drug targets where other technologies fall short. With a highly experienced team, this fundraising, backed by an impressive syndicate of world-class investors, will allow Nucleome to explore the dark genome and develop its exciting pipeline of potential drug targets. Oxford Science Enterprises is proud to have supported the Company since its inception and continues to do so, and we look forward to working with the team through this exciting time of growth.”

– Ends –

For more information, please contact:

Nucleome Therapeutics
Dr Danuta Jeziorska, Chief Executive Officer & Founder
contact@nucleome.com

Consilium Strategic Communications
Mary-Jane Elliott/Sukaina Virji/Stella Lempidaki
Nucleome@consilium-comms.com

About Nucleome Therapeutics
Nucleome Therapeutics is decoding the dark matter of the human genome to uncover novel ways to treat disease. The dark genome holds more than 90% of disease-linked genetic variants whose value remains untapped, representing a significant opportunity for drug discovery and development. The Company has the unique ability to link these variants to gene function and precisely map disease pathways. Nucleome’s cell type-specific platform creates high resolution 3D genome structure maps and enables variant functional validation at scale in primary cell types, enabling the discovery and development of novel, better and safer drugs. The initial focus of the company is on lymphocytes and related autoimmune disease. Nucleome’s ambition is to build a robust pipeline of drug assets, with corresponding biomarkers. Nucleome Therapeutics was founded by leading experts in gene regulation from the University of Oxford. For more information, please visit www.nucleome.com.

About M Ventures
M Ventures is the strategic, corporate venture capital arm of Merck KGaA, Darmstadt, Germany. From its headquarters in the Netherlands and offices in Germany, USA and Israel, M Ventures invests globally in transformational ideas driven by innovative entrepreneurs. Taking an active role in its portfolio companies, M Ventures teams up with management teams and co-investors to translate scientific discoveries into commercial success. M Ventures focuses on identifying and financing novel solutions to some of the most difficult challenges, through company creation and equity investments in fields that will impact the vitality and sustainability of Merck KGaA, Darmstadt, Germany ‘s current and future businesses. For more information, visit www.m-ventures.com.

About Pfizer Ventures
Pfizer Ventures, the venture capital arm of Pfizer Inc., was founded in 2004 and invests for return in areas of current or future strategic interest to Pfizer. Pfizer Ventures seeks to remain at the forefront of life science advances, looking to identify and invest in emerging companies that are developing transformative medicines and technologies that have the potential to enhance Pfizer’s pipeline and shape the future of our industry.

About British Patient Capital

British Patient Capital is the trading name of British Patient Capital Limited, a wholly-owned commercial subsidiary of British Business Bank plc, the UK government’s economic development bank. It forms part of the British Business Bank’s plc’s commercial arm. Its mission is to enable long-term investment in innovative firms led by ambitious entrepreneurs who want to build large scale businesses. Launched in June 2018, British Patient Capital has £2.5bn to invest over 10 years in venture and venture growth capital to support high growth potential innovative UK businesses in accessing the long-term financing they require to scale up. Find out more at britishpatientcapital.co.uk.

About Oxford Science Enterprises
Oxford Science Enterprises (OSE) is an independent, billion-pound investment company, created in 2015 to found, fund and build transformational businesses via its unique partnership with the University of Oxford, the world’s #1 research university.
This partnership enables OSE to work with the brightest academic minds tackling the world’s toughest challenges and guarantees unrivalled access to their scientific research.
In collaboration with its global network of entrepreneurs and advisers, OSE shapes and nurtures complex ideas into successful businesses, while targeting attractive returns for shareholders.
Actively focused on a core portfolio of around 40 companies spanning three high-growth, high-impact sectors – Life Sciences, Health Tech, and Deep Tech – the company adopts a flexible, long-term investment approach, recognising the path from ground-breaking research to global markets takes time and resilience.
To date, OSE has invested £0.5 billion in over 80 ambitious companies built on Oxford science.
A key player in Oxford’s entrepreneurial ecosystem, OSE is highly motivated to foster an environment that catalyses pioneering research and steers it to commercial success.
Find out more: oxfordscienceenterprises.com | Twitter | LinkedIn